Marcuzzi A, Loganes C, Valencic E, Piscianz E, Monasta L, Bilel S, Bortul R, Celeghini C, Zweyer M, Tommasini A. Neuronal Dysfunction Associated with Cholesterol Deregulation. Int J Mol Sci 2018;19(5)

Agostinis C, Rami D, Zacchi P, Bossi F, Stampalija T, Mangogna A, Amadio L, Vidergar R, Brumatti LVecchi, Ricci G, Celeghini C, Radillo O, Sargent I, Bulla R. Pre-eclampsia affects procalcitonin production in placental tissue. Am J Reprod Immunol 2018;79(4):e12823.

Marcuzzi A, Loganes C, Celeghini C, Kleiner G. Repositioning of Tak-475 In Mevalonate Kinase Disease: Translating Theory Into Practice. Curr Med Chem 2018;25(24):2783-2796.

Marcuzzi A, Piscianz E, Zweyer M, Bortul R, Loganes C, Girardelli M, Baj G, Monasta L, Celeghini C. Geranylgeraniol and Neurological Impairment: Involvement of Apoptosis and Mitochondrial Morphology. Int J Mol Sci 2016;17(3):365.

Trapella C, Voltan R, Melloni E, Tisato V, Celeghini C, Bianco S, Fantinati A, Salvadori S, Guerrini R, Secchiero P, Zauli G. Design, Synthesis, and Biological Characterization of Novel Mitochondria Targeted Dichloroacetate-Loaded Compounds with Antileukemic Activity. J Med Chem 2015;

Perri P, Zauli G, Gonelli A, Milani D, Celeghini C, Lamberti G, Secchiero P. TNF-related apoptosis inducing ligand in ocular cancers and ocular diabetic complications. Biomed Res Int 2015;2015:424019.

Cervellati C, Secchiero P, Bonaccorsi G, Celeghini C, Zauli G. Association of serum tumor necrosis factor-related apoptosis inducing ligand with body fat distribution as assessed by dual X-rays absorptiometry. Mediators Inflamm 2014;2014:306848.

Celeghini C, Not T, Norcio A, Monasta L, Secchiero P. Levels of circulating TNF-related apoptosis-inducing ligand in celiac disease. Exp Ther Med 2014;8(6):1906-1908.

Gasparini C, Celeghini C, Monasta L, Zauli G. NF-?B pathways in hematological malignancies. Cell Mol Life Sci 2014;71(11):2083-102.

Ura B, Feriotto G, Monasta L, Bilel S, Zweyer M, Celeghini C. Potential role of circulating microRNAs as early markers of preeclampsia. Taiwan J Obstet Gynecol 2014;53(2):232-4.

Agnoletto C, Melloni E, Casciano F, Rigolin GMatteo, Rimondi E, Celeghini C, Brunelli L, Cuneo A, Secchiero P, Zauli G. Sodium dichloroacetate exhibits anti-leukemic activity in B-chronic lymphocytic leukemia (B-CLL) and synergizes with the p53 activator Nutlin-3. Oncotarget 2014;5(12):4347-60.

Zauli G, Celeghini C, Monasta L, Martinelli M, Luppi S, Gonelli A, Grill V, Ricci G, Secchiero P. Soluble TRAIL is present at high concentrations in seminal plasma and promotes spermatozoa survival. Reproduction 2014;148(2):191-8.

Bosco R, Rabusin M, Voltan R, Celeghini C, Corallini F, Capitani S, Secchiero P. Anti-leukemic activity of dasatinib in both p53(wild-type) and p53(mutated) B malignant cells. Invest New Drugs 2012;30(1):417-22.

Rimondi E, di Iasio MGrazia, Gonelli A, Celeghini C, Secchiero P, Zauli G. Hydrogen sulfide down-regulates the expression and release of osteoprotegerin (OPG) by vascular endothelial cells. Invest New Drugs 2012;30(4):1731-5.

Secchiero P, Melloni E, Voltan R, Norcio A, Celeghini C, Zauli G. MCL1 down-regulation plays a critical role in mediating the higher anti-leukaemic activity of the multi-kinase inhibitor Sorafenib with respect to Dasatinib. Br J Haematol 2012;157(4):510-4.

Zauli G, Celeghini C, Melloni E, Voltan R, Ongari M, Tiribelli M, di Iasio MGrazia, Lanza F, Secchiero P. The sorafenib plus nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of FLT3 and p53 status. Haematologica 2012;97(11):1722-30.

Secchiero P, Bosco R, Celeghini C, Zauli G. Recent advances in the therapeutic perspectives of Nutlin-3. Curr Pharm Des 2011;17(6):569-77.

Corallini F, Celeghini C, Rimondi E, di Iasio MGrazia, Gonelli A, Secchiero P, Zauli G. Trail down-regulates the release of osteoprotegerin (OPG) by primary stromal cells. J Cell Physiol 2011;226(9):2279-86.

Zauli G, Toffoli B, di Iasio MGrazia, Celeghini C, Fabris B, Secchiero P. Treatment with recombinant tumor necrosis factor-related apoptosis-inducing ligand alleviates the severity of streptozotocin-induced diabetes. Diabetes 2010;59(5):1261-5.